Skip to main content

Table 4 Susceptibility of ICU and non-ICU ward subsets of lower respiratory tract infection isolates of P. aeruginosa and Enterobacterales to C/T and comparator agentsa,b,c – SMART 2018–2019, United States

From: Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Species/ward type n % Susceptible % MDR
C/T P/T FEP CAZ CRO ATM MEM IMI LVX AMK
P. aeruginosad
 ICU 495 96.0 72.3 78.0 76.6 NA 68.1 72.9 64.4 66.7 96.2 17.8
 Non-ICU 583 96.7 79.4 83.0 82.9 NA 72.2 79.8 69.0 61.9 96.6 10.5
Enterobacteralese
 ICU 1005 91.3 87.4 89.4 83.2 80.5 83.3 97.5 87.5 81.7 99.0 13.0
 Non-ICU 726 92.6 89.3 89.4 83.3 79.6 85.1 98.5 85.1 83.0 98.6 11.7
P. aeruginosa + Enterobacterales
 ICU 1500 92.9 82.4 85.6 81.0 NA 78.3 89.4 79.9 76.7 98.1 14.6
 Non-ICU 1309 94.4 84.9 86.6 83.1 NA 79.4 90.1 77.9 73.6 97.7 11.2
  1. a Abbreviations: C/T, ceftolozane/tazobactam; P/T, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ATM, aztreonam; MEM, meropenem; IMI, impenem; LVX, levofloxacin; AMK, amikacin; NA, not available
  2. b Table does not show results for colistin because P. aeruginosa and Enterobacterales cannot be categorized as susceptible to colistin using CLSI M100 (2020) MIC breakpoint criteria
  3. c Statistically significant differences between ICU and non-ICU are shown in bold font
  4. d Of the 1237 isolates P. aeruginosa, 48 were from emergency rooms and 111 did not have a location provided and were excluded from this analysis
  5. e Of the 1938 isolates of Enterobacterales, 57 were from emergency rooms and 150 did not have a location provided and were excluded from this analysis